Journal articles: 'Senile dementia Treatment Australia'

1

Stout, I. H. "Treatment of pre-senile dementia patients." Bulletin of the Royal College of Psychiatrists 11, no. 9 (September 1987): 312–13. http://dx.doi.org/10.1192/s0140078900017909.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bruyn, G. W. "Diagnosis and treatment of senile dementia." Journal of the Neurological Sciences 95, no. 2 (February 1990): 235. http://dx.doi.org/10.1016/0022-510x(90)90249-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Stout, I. H. "Treatment of pre-senile dementia patients." Psychiatric Bulletin 11, no. 9 (September 1, 1987): 312–13. http://dx.doi.org/10.1192/pb.11.9.312-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Grossmann, W., A. Standl, U. May, H. van Laak, and H. Hirche. "Naftidrofuryl in the Treatment of Mild Senile Dementia." Pharmacopsychiatry 23, no. 06 (November 1990): 265–73. http://dx.doi.org/10.1055/s-2007-1014517.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Markstein, R. "Pharmacological Approaches in the Treatment of Senile Dementia." European Neurology 29, no. 3 (1989): 33–41. http://dx.doi.org/10.1159/000116479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Steiger, William A., Marilyn Mendelson, Terry Jenkins, Marie Smith, and Ruth Gay. "Effects of Naloxone in Treatment of Senile Dementia." Journal of the American Geriatrics Society 33, no. 2 (February 1985): 155. http://dx.doi.org/10.1111/j.1532-5415.1985.tb02286.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Honjo, H., M. Urabe, K. Iwasa, T. Okubo, H. Tsuchiya, N. Kikuchi, M. Hayashi, and K. Hayashi. "A47 Estrogen treatment for senile dementia-Alzheimer's type." Maturitas 27 (November 1996): 15. http://dx.doi.org/10.1016/s0378-5122(97)80884-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sarter, Martin, Herbert H. Schneider, and David N. Stephens. "Treatment strategies for senile dementia: antagonist β-carbolines." Trends in Neurosciences 11, no. 1 (January 1988): 13–17. http://dx.doi.org/10.1016/0166-2236(88)90042-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Yi, W. Jian, D. Sinbon, P. Shuching, and L. Bolan. "Ginkgo biloba in the treatment of senile dementia." European Neuropsychopharmacology 6 (June 1996): 187. http://dx.doi.org/10.1016/0924-977x(96)88178-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

CHENG, Hai-ying, and Dong-qi CHENG. "Progress in Research on Acupuncture Treatment of Senile Dementia." Journal of Traditional Chinese Medicine 29, no. 3 (September 2009): 224–33. http://dx.doi.org/10.1016/s0254-6272(09)60071-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

CHEN, Li-ping, Fa-wei WANG, Fang ZUO, Jian-jun JIA, and Wei-guo JIAO. "Clinical Research on Comprehensive Treatment of Senile Vascular Dementia." Journal of Traditional Chinese Medicine 31, no. 3 (September 2011): 178–81. http://dx.doi.org/10.1016/s0254-6272(11)60036-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Nappi, Giuseppe, Giorgio Bono, Paola Merlo, Alessandro Borromei, Carlo Caltagirone, Cirino Lomeo, Nicola Martucci, Giovanni Fabbrini, Karin Annoni, and Angelo Battaglia. "Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia." Clinical Drug Investigation 13, no. 6 (June 1997): 308–16. http://dx.doi.org/10.2165/00044011-199713060-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Oram, Julian John, and Madeleine Elma Ogden. "Treatment of senile dementia with thyrotrophin releasing hormone and clomiphene." International Journal of Geriatric Psychiatry 2, no. 2 (April 1987): 125–26. http://dx.doi.org/10.1002/gps.930020211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

TSUJI, SHOJI. "Nerve. Diagnosis of the senile dementia and present states of treatment." Nihon Naika Gakkai Zasshi 86, no. 3 (1997): 420–24. http://dx.doi.org/10.2169/naika.86.420.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Gottfries, C. G. "Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment." Psychopharmacology 86, no. 3 (1985): 245–52. http://dx.doi.org/10.1007/bf00432208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Fleischhacker, W. Wolfgang, Astrid Buchgeher, and Harald Schubert. "Memantine in the treatment of senile dementia of the Alzheimer type." Progress in Neuro-Psychopharmacology and Biological Psychiatry 10, no. 1 (January 1986): 87–93. http://dx.doi.org/10.1016/0278-5846(86)90047-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Summers, William Koopmans, Lawrence Victor Majovski, Gary Martin Marsh, Kenneth Tachiki, and Arthur Kling. "Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type." New England Journal of Medicine 315, no. 20 (November 13, 1986): 1241–45. http://dx.doi.org/10.1056/nejm198611133152001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Jansen, Winfried, G. W. Bruckner, and P. Jansen. "The Treatment of Senile Dementia Associated with Cerebrovascular Insufficiency: A Comparative Study of Buflomedil and Dihydrogenated Ergot Alkaloids." Journal of International Medical Research 13, no. 1 (January 1985): 48–53. http://dx.doi.org/10.1177/030006058501300107.

Full text

Abstract:

Seventy-six patients took part in a randomized, comparative study of the efficacy of buflomedil hydrochloride and dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency. Efficacy was assessed by the patients' performance in four psychometric tests. The results showed that a trend in favour of the buflomedil group in three of the tests became statistically significant in the fourth. Both drugs appeared to be safe, causing no marked adverse reactions. In conclusion, buflomedil is as effective or more effective than dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency and could prove a valuable addition to long-term therapy if further studies support the trend shown in this study.

APA, Harvard, Vancouver, ISO, and other styles

19

Kuznetsova, Olga Yu, and Irina E. Moiseeva. "Features of palliative care for patients with dementia." Russian Family Doctor 21, no. 2 (June 15, 2017): 5–12. http://dx.doi.org/10.17816/rfd201725-12.

Full text

Abstract:

The article presents some features of palliative care for elderly and senile patients with dementia. The types and purposes of palliative care for patients with cognitive impairment, the principles of planning of palliative care, the features of nutrition of patients with dementia, the issues of assessing the pain syndrome and the treatment of co-morbidities in patients with dementia are considered.

APA, Harvard, Vancouver, ISO, and other styles

20

Huang, Min, Siyan Chen, Yubin Liang, and Yi Guo. "The Role of Berberine in the Multi-Target Treatment of Senile Dementia." Current Topics in Medicinal Chemistry 16, no. 8 (November 11, 2015): 867–73. http://dx.doi.org/10.2174/1568026615666150827095433.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Summers, WK, LV Majovski, GM Marsh, K. Tachiki, and A. Kling. "Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer??s type." Alzheimer Disease & Associated Disorders 1, no. 2 (1987): 110. http://dx.doi.org/10.1097/00002093-198701020-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Saito, Hiroshi, and Nobuyoshi Nishiyama. "Drug evaluations for the treatment of senile dementia using neuronal cell cultures." Japanese Journal of Pharmacology 49 (1989): 19. http://dx.doi.org/10.1016/s0021-5198(19)43017-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Rong-sen, Meng, Li Qing-ming, Wei Chang-xiu, Chen Bo, Liao Hong-ying, and Zhou Yu-tian. "Clinical observation and mechanism study on treatment of senile dementia with Naohuandan." Chinese Journal of Integrative Medicine 11, no. 2 (June 2005): 111–16. http://dx.doi.org/10.1007/bf02836466.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Keim, Kevin L., and B�la Kiss. "New drug strategies in the treatment of senile dementia of different origin." Drug Development Research 14, no. 3-4 (1988): 181. http://dx.doi.org/10.1002/ddr.430140302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Zheng, Wenxin, Xinyao Sun, and Jianghua Liu. "Efficacy of Donepezil Hydrochloride plus Olanzapine for Senile Dementia and Its Effect on the Recovery of Cognitive Function." Evidence-Based Complementary and Alternative Medicine 2022 (August 11, 2022): 1–5. http://dx.doi.org/10.1155/2022/4156312.

Full text

Abstract:

Objective. To investigate the efficacy of donepezil hydrochloride plus olanzapine for senile dementia and its effect on the recovery of cognitive function. Methods. A total of 60 patients with senile dementia admitted to our hospital from April 2020 to July 2021 were recruited and assigned to receive either olanzapine alone (observation group) or donepezil hydrochloride plus olanzapine (experimental group) via the random number table method, with 30 patients in each group. Results. The combined therapy resulted in significantly higher clinical efficacy versus monotherapy of olanzapine ( P < 0.05 ). Before treatment, the difference in the scores of cognitive function between the two groups did not come up to the statistical standard ( P > 0.05 ). Donepezil hydrochloride plus olanzapine was associated with significantly higher scores of cognitive function in patients versus olanzapine alone ( P < 0.05 ). The two groups had a similar incidence of adverse reactions ( P > 0.05 ). Conclusion. Donepezil hydrochloride plus olanzapine substantially enhances the recovery of cognitive function of patients with senile dementia and features a manageable safety. Further trials are, however, required prior to clinical promotion.

APA, Harvard, Vancouver, ISO, and other styles

26

Singh, Mahaveer, Kushali D, and Vinay C. H. "Comparison Study of Various Nano Technology Formulation of Curcumin in Treatment of Alzheimer’s Disease." Asian Journal of Pharmaceutical Research and Development 8, no. 3 (June 15, 2020): 99–103. http://dx.doi.org/10.22270/ajprd.v8i3.743.

Full text

Abstract:

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cognitive deterioration affecting day to day living and behavioural activities. It is commonest cause of senile and pre-senile dementia. In Alzheimer’s disease, a peptide referred as amyloid beta aggregates (oligomers), and accumulates in the brain to form deposits called as amyloid plaques. According to the world health organization (WHO), 5% of men and 6% of women of above 60 years are victims with Alzheimer’s type dementia globally. In India prevalence of dementia is 33.6%, of which AD contributes approximately 54% and vascular dementia constitutes approximately 39%. Patients with the prolonged use of some Non-steroidal anti-inflammatory (NSAID) drugs such as ibuprofen have lower risk of developing the symptoms of AD; however the chronic use of NSAID can produce a toxic effect on the kidney, liver and GI tract. Recent studies have demonstrated that a curcumin delivery system based on nanoscience and nanotechnology increases the therapeutic potential of this compound. Specifically, several nano-sized carriers such as phospholipid vesicles (liposomes), micelles, solid lipid nanoparticles, polymeric nanoparticles, emulsions, proteins and other molecular complexes have been developed for the efficient delivery of curcumin. Nano particles have demonstrated the enhanced Bioavailability of curcumin including circulation time in the blood. Various nano technology drug delivery system of curcumin showed increased Bio accessibility during treatment of Alzheimer’s disease.

APA, Harvard, Vancouver, ISO, and other styles

27

McKeith, I. G., R. H. Perry, A. F. Fairbairn, S. Jabeen, and E. K. Perry. "Operational criteria for senile dementia of Lewy body type (SDLT)." Psychological Medicine 22, no. 4 (November 1992): 911–22. http://dx.doi.org/10.1017/s0033291700038484.

Full text

Abstract:

SynopsisRecent reports have suggested that brain stem and cortical Lewy body formation may identify a neurodegenerative disorder in elderly demented individuals which accounts for up to 20% of cases of senile dementia coming to autopsy. Retrospective analysis of case notes of 21 autopsy patients with neuropathologically proven senile dementia of Lewy body type (SDLT) and 37 cases with neuropathologically proven Alzheimer's disease (AD) identified a characteristic clinical syndrome in SDLT. Fluctuating cognitive impairment; psychotic features including visual and auditory hallucinations, and paranoid delusions; depressive symptoms; falling and unexplained losses of consciousness were all seen significantly more often than in AD.Over half of the SDLT patients in this series who were given neuroleptics in standard dose showed acute and often irreversible adverse reactions indicative of a neuroleptic sensitivity syndrome. The survival time of drug treated patients was reduced by 50%.Operational criteria to aid in the clinical distinction between SDLT and AD patients are proposed and hypotheses regarding possible aetiology and treatment discussed.

APA, Harvard, Vancouver, ISO, and other styles

28

LIN, Zu-hui. "QIU Chang-lin's Experience in the Differential Treatment of Senile Dementia Based on Phlegm." Journal of Traditional Chinese Medicine 29, no. 2 (June 2009): 131–36. http://dx.doi.org/10.1016/s0254-6272(09)60049-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

PEARLSON, GODFREY D. "Normal Aging, Alzheimer's Disease, and Senile Dementia: Aspects on Etiology, Pathogenesis, Diagnosis and Treatment." American Journal of Psychiatry 143, no. 10 (October 1986): 1302. http://dx.doi.org/10.1176/ajp.143.10.1302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Findlay, D. J., J. Sharma, J. McEwen, B. R. Ballinger, W. J. MaClennan, and A. M. McHarg. "Double-blind controlled withdrawal of thioridazine treatment in elderly female inpatients with senile dementia." International Journal of Geriatric Psychiatry 4, no. 2 (March 1989): 115–20. http://dx.doi.org/10.1002/gps.930040210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Quirion, R., J. C. Martel, Y. Robitaille, P. Etienne, P. Wood, N. P. V. Nair, and S. Gauthier. "Neurotransmitter and Receptor Deficits in Senile Dementia of the Alzheimer Type." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 13, S4 (November 1986): 503–10. http://dx.doi.org/10.1017/s0317167100037215.

Full text

Abstract:

Abstract:Multiple neurotransmitter systems are affected in senile dementia of the Alzheimer's type (SDAT). Among them, acetylcholine has been most studied. It is now well accepted that the activity of the enzyme, choline acetyltransferase (ChAT) is much decreased in various brain regions including the frontal and temporal cortices, hippocampus and nucleus basalis of Meynert (nbm) in SDAT. Cortical M2-muscarinic and nicotinic cholinergic receptors are also decreased but only in a certain proportion (30-40%) of SDAT patients. For other systems, it appears that cortical serotonin (5-HT)-type 2 receptor binding sites are decreased in SDAT. This diminution in 5-HT2 receptors correlates well with the decreased levels of somatostatin-like immunoreactive materials found in the cortex of SDAT patients. Cortical somatostatin receptor binding sites are decreased in about one third of SDAT patients. Finally, neuropeptide Y and neuropeptide Y receptor binding sites are distributed in areas enriched in cholinergic cell bodies and nerve fiber terminals and it would be of interest to determine possible involvement of this peptide in SDAT. Thus, it appears that multi-drug clinical trials should be considered for the treatment of SDAT.

APA, Harvard, Vancouver, ISO, and other styles

32

Kanorskii, S. G. "Atrial fibrillation in old age: risk management and features of the use of direct oral anticoagulants." Kardiologiia 61, no. 6 (July 1, 2021): 79–87. http://dx.doi.org/10.18087/cardio.2021.6.n1627.

Full text

Abstract:

Senile patients with atrial fibrillation (AF) are at a higher risk of thromboembolism and hemorrhage than younger patients. Three direct oral anticoagulants (DOAC), apixaban, dabigatran, and rivaroxaban, are registered in the Russian Federation and are extensively used for prevention of stroke in patients with AF. The DOAC treatment of older patients requires considering peculiarities of these patients, clinical situation and properties of individual drugs to achieve the balance of efficiency and safety and a comprehensive protection. According to studies of real clinical practice DOAC may have advantages over warfarin (reduced risk of fractures, diabetes mellitus, and dementia). Compliance with and constancy of the DOAC treatment are important for its efficiency, particularly in senile age. Results of clinical trials and real clinical practice studies have confirmed that rivaroxaban may provide a comprehensive protection for a senile patient with AF due to favorable indexes of efficiency and safety, beneficial effect on the risk of coronary events and impairment оf renal function, whereas once a day dosing of rivaroxaban improves the compliance with this treatment and its constancy.

APA, Harvard, Vancouver, ISO, and other styles

33

Fujikawa, Tokumi, Terumichi Takahashi, Akiko Kinoshita, Hiroaki Kajiyama, Akiko Kurata, Hidehisa Yamashita, and Shigeto Yamawaki. "Quetiapine Treatment for Behavioral and Psychological Symptoms in Patients with Senile Dementia of Alzheimer Type." Neuropsychobiology 49, no. 4 (2004): 201–4. http://dx.doi.org/10.1159/000077367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Schmidt, Joachim, Hans-Dieter Fischer, and Christian Wustmann. "Strategies and new aspects in the pharmacology of drugs for the treatment of senile dementia." Drug Development Research 14, no. 3-4 (1988): 251–62. http://dx.doi.org/10.1002/ddr.430140317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Meghani, Monika, Pawan Kumar Mahawar, Kapil Sharma, and Gurvindar Singh. "A Review on Biological Activity of Heterocyclic Nucleus Carbazole." Asian Journal of Pharmaceutical Research and Development 8, no. 3 (June 15, 2020): 152–61. http://dx.doi.org/10.22270/ajprd.v8i3.708.

Full text

Abstract:

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cognitive deterioration affecting day to day living and behavioural activities. It is commonest cause of senile and pre-senile dementia. In Alzheimer’s disease, a peptide referred as amyloid beta aggregates (oligomers), and accumulates in the brain to form deposits called as amyloid plaques. According to the world health organization (WHO), 5% of men and 6% of women of above 60 years are victims with Alzheimer’s type dementia globally. In India prevalence of dementia is 33.6%, of which AD contributes approximately 54% and vascular dementia constitutes approximately 39%. Patients with the prolonged use of some Non-steroidal anti-inflammatory (NSAID) drugs such as ibuprofen have lower risk of developing the symptoms of AD; however the chronic use of NSAID can produce a toxic effect on the kidney, liver and GI tract. Recent studies have demonstrated that a curcumin delivery system based on nanoscience and nanotechnology increases the therapeutic potential of this compound. Specifically, several nano-sized carriers such as phospholipid vesicles (liposomes), micelles, solid lipid nanoparticles, polymeric nanoparticles, emulsions, proteins and other molecular complexes have been developed for the efficient delivery of curcumin. Nano particles have demonstrated the enhanced Bioavailability of curcumin including circulation time in the blood. Various nano technology drug delivery system of curcumin showed increased Bio accessibility during treatment of Alzheimer’s disease.

APA, Harvard, Vancouver, ISO, and other styles

36

Bulgakova, S. V., E. V. Treneva, and N. O. Zakharova. "Hypovitaminosis D in the elderly: relationship with sarcopenia and dementia (review of literature)." Russian Clinical Laboratory Diagnostics 66, no. 1 (February 10, 2021): 5–9. http://dx.doi.org/10.18821/0869-2084-2021-66-1-5-9.

Full text

Abstract:

The growth in the world population of elderly and senile people provokes interest in the processes and mechanisms leading to aging and age-associated diseases. Hypovitaminosis D is common in geriatric patients and has been suggested by a number of authors as a cause of diseases such as dementia and sarcopenia. This literature review is devoted to the analysis of the role of vitamin D in the development of the above diseases, their prevention and treatment.

APA, Harvard, Vancouver, ISO, and other styles

37

Wang, Zongqin, Yingying Feng, Yanyan Wang, Hui Qiu, Zhongyang Rui, Mingxing Li, and Lihua Lv. "Meta-Analysis of the Efficacy and Safety of Olanzapine versus Clozapine when Treating Senile Dementia." Computational and Mathematical Methods in Medicine 2022 (August 11, 2022): 1–12. http://dx.doi.org/10.1155/2022/5046761.

Full text

Abstract:

Objective. To systematically assess the safety and efficacy of olanzapine versus clozapine when treating senile dementia and to provide evidence-based medicine basis for its promotion and use. Methods. PubMed, Embase, ScienceDirect, Cochrane Library, China Knowledge Network Database (CNKI), China VIP Database, Wanfang Database, and China Biomedical Literature Database (CBM) online database were searched for randomized controlled trials (RCT) of olanzapine and clozapine when treating senile dementia. The retrieval time limit is from the establishment of the database to the present. The data were extracted independently by two researchers, and the bias risk of each contained literature was analyzed in accordance with the standard of Cochrane Handbook 5.3. RevMan 5.4 statistical software was used to analyze the collected data by meta-analysis. Results. Finally, 6 randomized controlled trial articles were included, with a total of 490 samples. Meta-analysis of clinical efficacy showed that the clinical efficacy was similar and there was no significant difference ( P > 0.05 ). Two articles used Alzheimer’s disease pathological behavior rating scale (BEHAVE-AD) to compare the pathological behavior of different stages after treatment. Statistical analysis showed that there was no significant difference between the total score of BEHAVE-AD and the scores of each factor in each week after treatment. The non-treatment adverse reaction scale (TESS) of the study group and the control group was analyzed by meta-analysis. The TESS score of the study group after treatment was significantly lower than that of the control group. The BPRS scores of different stages after treatment were analyzed by meta-analysis, and there was no significant difference in the total score and factor scores of BPRS in each week after treatment. Two clinical trials reported the incidence of neurological symptoms after treatment. Olanzapine and clozapine treatment can effectively reduce the risk of aging. There was no significant difference in the incidence of neurological symptoms in patients with dementia ( P > 0.05 ). According to the analysis of meat products, the incidence of adverse reactions in the study group was significantly lower than that in the control group ( P < 0.05 ). Conclusion. Olanzapine and clozapine have similar efficacy when treating mental and behavioral disorders in patients with senile dementia, in which olanzapine is more effective in improving the symptoms of patients with Alzheimer’s disease (AD), with less adverse reactions and high safety, which is worth popularizing in clinical practice. However, more studies and follow-up with higher methodological quality and longer intervention time are needed to further verify.

APA, Harvard, Vancouver, ISO, and other styles

38

Moorthi, Vinayaga, and Preethi B. "A REVIEW ON ALZHIMER’S DISEASE: PATHOLOGY, MOLECULAR CONDITIONS, MANAGEMNT AND CAUSES." Asian Journal of Pharmaceutical and Clinical Research 10, no. 5 (May 1, 2017): 27. http://dx.doi.org/10.22159/ajpcr.2017.v10i5.16942.

Full text

Abstract:

Alzheimer’s disease (AD) is a neurodegenerative disorder that starts slowly, progressively leads to death and contributes to about 60-70% cases of dementia. AD is characterized with Senile Plaques (SPs) and neurofibrillary tangles (NFTs) and the major symptoms include problems with language, dis-orientation of words, unable to manage self-care, memory loss and behavioural issues which gradually lead to completely lose bodily functions later. The actual cause for the disease is not known till date. Recent research show distinct paths that closely try to reveal various cytoplasmic, genetic, behavioural, environmental and epigenetic causes that may lead to the development of AD. Most likely all studies target the Senile Plaques, protein fragments called beta-amyloid and Neurofibrillary Tangles, twisted fibres of a protein called tau. Since, the exact causative mechanism is not yet clearly understood, ultimately finding a suitable treatment or management for the disease has also become an ominous challenge for researchers.Keywords: Alzheimer’s disease, Pathology, Phosphatase and tensin, Senile plaques, Neurofibrillary tangles

APA, Harvard, Vancouver, ISO, and other styles

39

Grishina, D. A., and A. B. Lokshina. "Issues of diagnosis and treatment of mild cognitive impairment." Meditsinskiy sovet = Medical Council, no. 21 (November 18, 2022): 46–53. http://dx.doi.org/10.21518/2079-701x-2022-16-21-46-53.

Full text

Abstract:

Cognitive impairment refers to frequent disorders in the elderly and senile, and their prevalence increases with age significantly. Non-dementia cognitive disorders mean a spectrum of changes in the cognitive sphere that precede the development of dementia over the course of many months and even years. Mild forms of cognitive impairment (MCI) are the most studied type of pre-dementia conditions, which in most cases represent a prodromal stage of disorders progressing over time to a dementia syndrome. Early identification of individuals with MCI is important because timely diagnosis of these disorders is expanding the potential impact of the secondary prevention and therapeutic intervention, which can delay or even prevent the onset of professional and social maladaptation due to development of dementia. The article considers the historical issues of studying these disorders, presents the modern principles of their classification and diagnostic criteria. A clinical observation of a patient with a polyfunctional non-amnestic type MCI syndrome is provided. The features of cognitive disorders typical for chronic cerebrovascular insufficiency, such as mental retardation, impaired activity arrangement, difficulties with generalisation in relative preservation of memory and orientation in combination with emotional and affective disorders are described. The authors discuss issues of treatment of MCI syndrome, which should be comprehensive and include the correction of all vascular risk factors, non-drug (regular physical activity, cognitive training) and pharmacological treatments aimed at improving cognitive performance. The article describes the possibilities of modern neuroprotective and symptomatic therapy of cognitive impairment, showing the role of choline alfoscerate in the treatment of MCI.

APA, Harvard, Vancouver, ISO, and other styles

40

Smith, Colin M. "Book Review: Normal Aging, Alzheimer's Disease and Senile Dementia: Aspects on Etiology, Pathogenesis, Diagnosis and Treatment." Canadian Journal of Psychiatry 32, no. 6 (August 1987): 489. http://dx.doi.org/10.1177/070674378703200622.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Cutler, Neal R., T. Daniel Fakouhi, Ward T. Smith, Hugh C. Hendrie, Fumisuke Matsuo, John J. Sramek, and Robert L. Herting. "Evaluation of Multiple Doses of Milacemide in the Treatment of Senile Dementia of the Alzheimer's Type." Journal of Geriatric Psychiatry and Neurology 6, no. 2 (April 1993): 115–19. http://dx.doi.org/10.1177/089198879300600210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Dehlin, O., B. Hedenrud, P. Jansson, and J. Norgard. "A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia." Acta Psychiatrica Scandinavica 71, no. 2 (February 1985): 190–96. http://dx.doi.org/10.1111/j.1600-0447.1985.tb01270.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

FERRERO, M. E., V. SANTINI, M. MANTOVANI, and G. PRINO. "Does successful treatment with glycosaminoglycan polysutphate in senile dementia indicate the pathogenetic mechanism of the disease?" Biochemical Society Transactions 17, no. 2 (April 1, 1989): 360. http://dx.doi.org/10.1042/bst0170360.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Harrison, Richard W. S., and Ian G. McKeith. "Senile dementia of lewy body type?a review of clinical and pathological features: Implications for treatment." International Journal of Geriatric Psychiatry 10, no. 11 (November 1995): 919–26. http://dx.doi.org/10.1002/gps.930101103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Annear, Michael J., and Peter Lucas. "Dementia in a regional hospital setting: contextual challenges and barriers to effective care." International Journal of Ageing and Later Life 12, no. 1 (August 13, 2018): 91–119. http://dx.doi.org/10.3384/ijal.1652-8670.17344.

Full text

Abstract:

Dementia is a growing public health problem, which may be under-recognised and poorly managed in regional hospitals. With projections of increasing dementia among older adults in regional and rural areas, knowledge about dementia and capacity of professionals to provide best-evidence care is paramount. This research investigates the challenges of dementia care in a publicly funded regional hospital in Australia. The study elucidates prevalence of dementia-related admissions, costs of treatment, length of stay and capacity for dementia care. A mixed methodology was employed in this study, including analysis of hospital records (N = 2405), dementia knowledge surveys (n = 50) and semi-structured interviews with clinical staff (n = 13). Hospital records showed that dementia-related admissions were lower than population prevalence reported in regional Australia. Dementia patients, however, attracted significantly higher treatment costs and greater length of stay than age-matched admissions who did not have a diagnosis of dementia. Clinicians reported several obstacles to effective dementia care, including staff knowledge deficits, environmental challenges, resource constraints and organisational factors.

APA, Harvard, Vancouver, ISO, and other styles

46

PEDRO, Matheus Kahakura Franco, Joseph Franklin Chenisz da SILVA, Samanta Fabricio Blattes da ROCHA, Francisco Manoel Branco GERMINIANI, Ricardo RAMINA, Hélio Afonso Ghizoni TEIVE, and Ricardo Krause Martinez de SOUZA. "Salomón Hakim: the man behind normal pressure hydrocephalus." Arquivos de Neuro-Psiquiatria 77, no. 10 (October 2019): 746–48. http://dx.doi.org/10.1590/0004-282x20190096.

Full text

Abstract:

ABSTRACT The illustrious Colombian Professor Salomón Hakim provided the annals of neurology with one of the most brilliant and original bodies of research on record, developing the concept of normal pressure hydrocephalus, as well as proving that ventricular shunting is an effective treatment. Thus, Professor Hakim proved that some of the dementias, at that time considered senile, could be successfully treated. Here the authors present an historical review of his main contributions, which continue to influence the study of dementia to this day.

APA, Harvard, Vancouver, ISO, and other styles

47

Senin, U., L. Parnetti, D. Cucinotta, D. Criscuolo, A. Longo, and G. Marini. "Clinical Experience with Aniracetam in the Treatment of Senile Dementia of the Alzheimer’s Type and Related Disorders." Drug Investigation 5, S1 (June 1993): 96–105. http://dx.doi.org/10.1007/bf03258430.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gavrilova, S. I., and T. P. Safarova. "Neurotrophins and Neurotrophic Therapy (Based on the Cerebrolysin Model) in the Treatment of Elderly Patients with Cognitive Disorders and Depression. Part 2." Psikhiatriya 19, no. 3 (October 14, 2021): 80–89. http://dx.doi.org/10.30629/2618-6667-2021-19-3-80-89.

Full text

Abstract:

Background: сognitive impairment and late depression, along with dementia, are the most common mental disorders in elderly and senile patients. Currently, more and more attention is being paid to preventive therapeutic approaches in the treatment of these conditions and to the study of drugs with multimodal neuroprotective and neurotrophic properties that contribute to the strengthening of the so-called endogenous system of protection and recovery of the brain, which is a kind of barrier to the incipient neurodegeneration. Objective: to present a review of domestic and foreign modern studies devoted to the study of the multimodal effects of the drug cerebrolysin, which has neurotrophin-like properties, and the results of its use in the treatment of cognitive disorders that do not reach the degree of dementia, as well as late depression. Material and methods: using the keywords “late age, mild cognitive disorders, depression, MCI syndrome, therapy, cerebrolysin”, we searched for scientifi c articles in the MEDLINE and PubMed databases for the period 2000–2020. Conclusion: the data presented in the review showed that cerebrolysin, acting as a multi-target drug, affects multiple molecular mechanisms of the pathogenesis of pre-dementia cognitive disorders and late-age depression. The drug detects a neurotrophin-like effect, improves the processes of neuroplasticity and can help enhance the protection and restoration of the brain under various pathological infl uences. Neurobiological studies and the results of a pilot prospective study indicate the preventive potential of cerebrolysin in preventing the development or slowing the progression of the neurodegenerative process of Alzheimer’s type. In the studies presented in the review, the ability of cerebrolysin to increase the effectiveness of modern antidepressant therapy (with second-generation drugs) in the elderly has been shown, presumably by potentiating the therapeutic effect of antidepressants or by improving their tolerability, which makes it possible to safely use higher doses of antidepressants in the elderly and senile patients.

APA, Harvard, Vancouver, ISO, and other styles

49

Gavrilova, S. I., and T. P. Safarova. "Neurotrophins and Neurotrophic Therapy (Based on the Cerebrolysin Model) in the Treatment of Elderly Patients with Cognitive Disorders and Depression. Part 2." Psikhiatriya 19, no. 3 (October 14, 2021): 80–89. http://dx.doi.org/10.30629/2618-6667-2021-19-3-80-89.

Full text

Abstract:

Background: сognitive impairment and late depression, along with dementia, are the most common mental disorders in elderly and senile patients. Currently, more and more attention is being paid to preventive therapeutic approaches in the treatment of these conditions and to the study of drugs with multimodal neuroprotective and neurotrophic properties that contribute to the strengthening of the so-called endogenous system of protection and recovery of the brain, which is a kind of barrier to the incipient neurodegeneration. Objective: to present a review of domestic and foreign modern studies devoted to the study of the multimodal effects of the drug cerebrolysin, which has neurotrophin-like properties, and the results of its use in the treatment of cognitive disorders that do not reach the degree of dementia, as well as late depression. Material and methods: using the keywords “late age, mild cognitive disorders, depression, MCI syndrome, therapy, cerebrolysin”, we searched for scientifi c articles in the MEDLINE and PubMed databases for the period 2000–2020. Conclusion: the data presented in the review showed that cerebrolysin, acting as a multi-target drug, affects multiple molecular mechanisms of the pathogenesis of pre-dementia cognitive disorders and late-age depression. The drug detects a neurotrophin-like effect, improves the processes of neuroplasticity and can help enhance the protection and restoration of the brain under various pathological infl uences. Neurobiological studies and the results of a pilot prospective study indicate the preventive potential of cerebrolysin in preventing the development or slowing the progression of the neurodegenerative process of Alzheimer’s type. In the studies presented in the review, the ability of cerebrolysin to increase the effectiveness of modern antidepressant therapy (with second-generation drugs) in the elderly has been shown, presumably by potentiating the therapeutic effect of antidepressants or by improving their tolerability, which makes it possible to safely use higher doses of antidepressants in the elderly and senile patients.

APA, Harvard, Vancouver, ISO, and other styles

50

Ferrari, E., D. Cucinotta, M. G. Albizatti, L. Bartorelli, N. Colombo, G. Ferretti, G. Galetti, et al. "Effectiveness and safety of posatirelin in the treatment of senile dementia: A multicenter, double-blind, placebo-controlled study." Archives of Gerontology and Geriatrics 26 (January 1998): 163–74. http://dx.doi.org/10.1016/s0167-4943(98)80024-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Senile dementia Treatment Australia'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles